Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201301150 Principal Investigator: Tan, Benjamin
Title: A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib
Phase: III Disease Site: Liver
Participating Site(s):
 
Main Campus
Map and Directions
South County
Map and Directions
St. Peters
Map and Directions
West County
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this study is to assess if regorafenib in combination with best supportive care is safe and will slow down the growth of tumor or even shrink the tumor and result in increased survival in patients who
experienced failure of previous sorafenib treatment.
 
More Information:
ClinicalTrials.Gov Link
Internal Protocol Documents (requires Siteman administrative database password)